Kineta Company Description
Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives.
It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy.
The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug.
KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, renal cell carcinoma, head and neck, renal cell, and colorectal cancers.
It is also developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells.
The company has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. is headquartered in Seattle, Washington.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
Contact Details
Address: 219 Terry Ave. N Seattle, Delaware 98109 United States | |
| Phone | 206 378 0400 |
| Website | kinetabio.com |
Stock Details
| Ticker Symbol | KANT |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Craig W. Philips | President and Secretary |
| Keith A. Baker | Chief Financial Officer |
| Dr. Thierry Guillaudeux Ph.D. | Chief Scientific Officer |
| Gary Gentges | Executive Vice President of Corporate Development |
| Pauline Kenny Esq., J.D. | Advisor |